Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

NCT03407170 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Accrual

Conditions

Advanced Melanoma

Interventions

BIOLOGICAL: pembrolizumab

Sponsor

Merck Sharp & Dohme LLC